Nursing home pharmacy providers and managed care pharmacy executives named Merck and Novartis, respectively, as the pharmaceutical companies that best meet their overall needs, according to new audit reports released by Newton, PA-based Scott-Levin Associates.
Nursing home pharmacy providers and managed care pharmacy executives named Merck and Novartis, respectively, as the pharmaceutical companies that best meet their overall needs, according to new audit reports released by Newton, PA-based Scott-Levin Associates.
Merck was named by a panel of nursing home and consultant pharmacists as the manufacturer that best meets the overall needs of long-term care pharmacists in the fall 1997 "Nursing Home Pharmacy Provider/Consultant Promotional Audit."
Companies were rated according to value-added services, best contracts, most knowledgeable sales representatives and overall assessment. Merck ranked first in all four categories for the second time in a row. Bristol-Myers Squibb took second; Eli Lilly & Co. ranked third; Bayer came in fourth; and Johnson & Johnson, Mylan, Pfizer and Purdue Frederick tied for fifth.
According to Scott-Levin, Johnson & Johnson and Pfizer made the most gains among this customer base. In the spring, they were ranked 36th and 37th, respectively. One panelist said: "Johnson & Johnson has a new start and seems to be dedicated to long-term care pharmacy." Another panelist said of Pfizer: "Having just become very active in long-term care, they are trying to learn as much as possible about the long-term care marketplace."
Novartis ranked first with managed care executives as the pharmaceutical company that best serves the managed care industry, according to the fall 1997 "Managed Care Pharmacy Executive Promotional Audit."
This was the second time in a row that Novartis took first place in this category. Its net score for the fall (tallied according to best mentions minus least mentions) was 26% higher than it was in the spring, and it's score was 56% higher that of second-place mention SmithKline Beecham.
Executives reported promotional activity from pharmaceutical firms over an eight-week period. They rated the companies according to their ability to meet managed care's needs in four areas: contracts, value-added services, knowledgeable sales reps and overall assessment.
Filling the top 10 spots, in descending order, were Novartis, SmithKline Beecham, Hoescht Marion Roussel, Merck, Zeneca, Bristol-Myers Squibb, Warner-Lambert, Pfizer, and TAP (tie) and Astra Merck.
According to managed care executives, Pfizer and TAP improved the most in 1997. Both companies received compliments for their supportive attitudes and good intentions. Of Pfizer, one executive said: "Pfizer is sponsoring programs and is willing to support our ideas much better than three years ago." TAP, others said, demonstrates "a strong desire to work with the managed care industry." PR
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.